首页> 外文期刊>Journal of cellular and molecular medicine. >MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C
【24h】

MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C

机译:MiR-138通过靶向GIT1和SEMA4C抑制非小细胞肺癌细胞的细胞增殖并逆转上皮-间质转化

获取原文
获取原文并翻译 | 示例
           

摘要

Non-small-cell lung cancer (NSCLC) is one of the most common and lethal malignant tumours worldwide with a poor 5-year survival rate. Recent studies indicated that miRNAs have been involved in the tumorigenic driver pathways in NSCLC, but the relevant molecular mechanisms are not well-understood. In this study, we investigated the biological functions and molecular mechanisms of miR-138 in human NSCLC. The effects of miR-138 on the NSCLC cell growth and epithelial-mesenchymal transition (EMT) were first examined. Then the targeting connections of miR-138 with G-protein-coupled receptor kinase-interacting protein 1 (GIT1) and semaphorin 4C (SEMA4C) were confirmed by dual luciferase reporter assays. Finally, the effects of GIT1 and SEMA4C on the NSCLC cell growth and EMT were investigated respectively. We found that the ectopic expression of miR-138 resulted in a significant inhibition of NSCLC growth and reversion of EMT. GIT1 and SEMA4C were identified as two novel targets of miR-138. Furthermore, GIT1 and SEMA4C knockdown inhibited the cell growth and reversed EMT, just like the effects of miR-138 overexpression on NSCLC cells, whereas ectopic expression of GIT1 and SEMA4C partly rescued the suppressive effects of miR-138 in NSCLC cells. These data represent a crucial step towards the understanding of the novel roles and molecular mechanism of miR-138, GIT1 and SEMA4C in NSCLC progression, which may provide some new targets or prognostic biomarkers for NSCLC treatment, thus having implications in translational oncology.
机译:非小细胞肺癌(NSCLC)是全球最常见和致命的恶性肿瘤之一,其5年生存率很低。最近的研究表明,miRNA已经参与了NSCLC的致瘤驱动途径,但是相关的分子机制尚未得到很好的理解。在这项研究中,我们调查了人类非小细胞肺癌中miR-138的生物学功能和分子机制。首先检查了miR-138对NSCLC细胞生长和上皮-间质转化(EMT)的影响。然后,通过双重荧光素酶报告基因分析证实了miR-138与G蛋白偶联受体激酶相互作用蛋白1(GIT1)和信号灯蛋白4C(SEMA4C)的靶向连接。最后,分别研究了GIT1和SEMA4C对NSCLC细胞生长和EMT的影响。我们发现,miR-138的异位表达导致对NSCLC生长和EMT逆转的显着抑制。 GIT1和SEMA4C被确定为miR-138的两个新靶标。此外,就像miR-138过表达对NSCLC细胞的作用一样,GIT1和SEMA4C抑制作用抑制细胞生长并逆转EMT,而GIT1和SEMA4C的异位表达部分挽救了miR-138在NSCLC细胞中的抑制作用。这些数据代表了理解miR-138,GIT1和SEMA4C在NSCLC进展中的新作用和分子机制的关键步骤,这可能为NSCLC治疗提供一些新的靶标或预后生物标志物,从而对翻译肿瘤学产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号